Pancreatic cancer: chemotherapy and radiotherapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

17 citing papers in PubMed.

1. Application of intrahepatic fiducial markers in carbon ion radiotherapy for pancreatic cancer-Achieving higher precision treatment.Journal of applied clinical medical physics · 2026
   Article
2. Advancing Radiobiology: Investigating the Effects of Photon, Proton, and Carbon-Ion Irradiation on PANC-1 Cells in 2D and 3D Tumor Models.Current oncology (Toronto, Ont.) · 2025
   Article
3. Extracellular derived-exosomal micrornas in pancreatic cancer: investigating their diagnostic importance and potential targets for the prevention and treatment in pancreatic cancer.Frontiers in oncology · 2025
   Review
4. Improved Therapeutic Delivery Targeting Clinically Relevant Orthotopic Human Pancreatic Tumors Engrafted in Immunocompromised Pigs Using Ultrasound-Induced Cavitation: A Pilot Study.Pharmaceutics · 2023
   Article
5. FOLFIRINOX Pharmacodynamic Interactions in 2D and 3D Pancreatic Cancer Cell Cultures.The AAPS journal · 2022
   Article
6. RETRACTED: Triazole Modified Tetraiodothyroacetic Acid Conjugated to Polyethylene Glycol, a Thyrointegrin αBiomedicines · 2022
   Article
7. A Combination of Radiotherapy, Hyperthermia, and Immunotherapy Inhibits Pancreatic Tumor Growth and Prolongs the Survival of Mice.Cancers · 2020
   Article
8. Stage IA Patients With Pancreatic Ductal Adenocarcinoma Cannot Benefit From Chemotherapy: A Propensity Score Matching Study.Frontiers in oncology · 2020
   Article
9. Phase Ib trial of gemcitabine with yttrium-90 in patients with hepatic metastasis of pancreatobiliary origin.Journal of gastrointestinal oncology · 2019
   Article
10. Comparison of Radiosensitization by HDAC Inhibitors CUDC-101 and SAHA in Pancreatic Cancer Cells.International journal of molecular sciences · 2019
    Article
11. Complex interplay between tumor microenvironment and cancer therapy.Frontiers of medicine · 2018
    Review
12. dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer.Cell proliferation · 2018
    Article
13. Biological determinants of radioresistance and their remediation in pancreatic cancer.Biochimica et biophysica acta. Reviews on cancer · 2017
    Review
14. The role of FADD in pancreatic cancer cell proliferation and drug resistance.Oncology letters · 2017
    Article
15. The Value of Survival Gains in Pancreatic Cancer from Novel Treatment Regimens.Journal of managed care & specialty pharmacy · 2017
    Article
16. MicroRNA-429 sensitizes pancreatic cancer cells to gemcitabine through regulation of PDCD4.American journal of translational research · 2017
    Article
17. Interventional Nanotheranostics of Pancreatic Ductal Adenocarcinoma.Theranostics · 2016
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as